{"id":"909bdfa7-6092-5733-8e0f-a3ed8517b4ce","stable_key":"a9dd23c6-978a-5755-8bd8-f29bd1fe0cda:nia-clin-nmn-liver-insulin","predicate":"does_not_improve_measured","statement":"The NMN trial did not find improved hepatic or adipose tissue insulin sensitivity; fasting metabolic measures, body composition and liver fat were also unchanged.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"10ccbc03-bea9-50ee-9c38-9ab54455367c","mechanism_event_label":"The muscle result did not extend to all insulin-responsive organs or to a general metabolic improvement.","subject":{"id":"d1c59139-db61-5fa0-a25d-40c3e625152e","slug":"nmn","display_name":"NMN","entity_type_key":"small_molecule"},"object":{"id":"6fd134c3-7f38-5947-b8df-6aa0ab09c143","slug":"hepatic-insulin-sensitivity","display_name":"Hepatic insulin sensitivity","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"10ccbc03-bea9-50ee-9c38-9ab54455367c","stable_key":"a9dd23c6-978a-5755-8bd8-f29bd1fe0cda:nia-clin-nmn-liver-insulin-event","event_type":"observed_intervention","label":"The muscle result did not extend to all insulin-responsive organs or to a general metabolic improvement.","description":"The NMN trial did not find improved hepatic or adipose tissue insulin sensitivity; fasting metabolic measures, body composition and liver fat were also unchanged.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"9e6e0631-7784-578c-a9ed-718d57e7cdcd","slug":"adipose-tissue-insulin-sensitivity","display_name":"Adipose tissue insulin sensitivity","entity_type_key":"cellular_process"},"role":"parallel_null_endpoint","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"d1c59139-db61-5fa0-a25d-40c3e625152e","slug":"nmn","display_name":"NMN","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"6fd134c3-7f38-5947-b8df-6aa0ab09c143","slug":"hepatic-insulin-sensitivity","display_name":"Hepatic insulin sensitivity","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"cross_nutrient","value_text":"Adipose tissue insulin sensitivity (parallel_null_endpoint)","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/niacin-clinical-sources/yoshino2021.txt\", \"locator\": \"Primary full report; exact character range, zero-based and end-exclusive\", \"file_sha256\": \"e4999dc5b9d3392d8180280727c424044b35249bb24c999c3bc863cd23e6c856\", \"start_char\": 6120, \"end_char\": 7140, \"text_sha256\": \"152262160f005f7aac5e078287acca1db556d35a8645d8892492723992dec2dc\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Randomized double-blind trial; 25 overweight or obese postmenopausal women with prediabetes completed","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"NMN 250 mg/day for 10 weeks; 13 NMN and 12 placebo participants","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Small selected female cohort. Tissue NAD concentration, NAD turnover and clinical outcomes differ. No lifespan or diabetes-prevention endpoint. Positive muscle findings do not establish whole-body or cross-population benefit.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Niacin research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"niacin","display_name":"Niacin (vitamin B3)","entity_type_key":"nutrient_element"}},{"dimension":"organism","value_text":"Homo sapiens","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The muscle result did not extend to all insulin-responsive organs or to a general metabolic improvement.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[nia-clin-yoshino2021] Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. (2021). https://pubmed.ncbi.nlm.nih.gov/33888596/ DOI: 10.1126/science.abe9985","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Skeletal muscle, PBMCs, liver and adipose insulin sensitivity","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"ec018c20-4872-5b14-b888-660c05c6ee26","evidence_kind":"source_excerpt","locator":"Lines 1529-1541","start_line":1529,"end_line":1541,"excerpt":"### nia-clin-nmn-liver-insulin\nThe NMN trial did not find improved hepatic or adipose tissue insulin sensitivity; fasting metabolic measures, body composition and liver fat were also unchanged.\nCondition category: normal\nnutrient_topic: Niacin research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The muscle result did not extend to all insulin-responsive organs or to a general metabolic improvement.\norganism: Homo sapiens\ntissue_or_cell_type: Skeletal muscle, PBMCs, liver and adipose insulin sensitivity\nexperimental_model: Randomized double-blind trial; 25 overweight or obese postmenopausal women with prediabetes completed\nlimitations: Small selected female cohort. Tissue NAD concentration, NAD turnover and clinical outcomes differ. No lifespan or diabetes-prevention endpoint. Positive muscle findings do not establish whole-body or cross-population benefit.\nexposure: NMN 250 mg/day for 10 weeks; 13 NMN and 12 placebo participants\ncross_nutrient: Adipose tissue insulin sensitivity (parallel_null_endpoint)\nevidence_span: {\"source_cache\": \"artifacts/niacin-clinical-sources/yoshino2021.txt\", \"locator\": \"Primary full report; exact character range, zero-based and end-exclusive\", \"file_sha256\": \"e4999dc5b9d3392d8180280727c424044b35249bb24c999c3bc863cd23e6c856\", \"start_char\": 6120, \"end_char\": 7140, \"text_sha256\": \"152262160f005f7aac5e078287acca1db556d35a8645d8892492723992dec2dc\"}\n[nia-clin-yoshino2021] Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. (2021). https://pubmed.ncbi.nlm.nih.gov/33888596/ DOI: 10.1126/science.abe9985","model_system":"Randomized double-blind trial; 25 overweight or obese postmenopausal women with prediabetes completed","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [nia-clin-yoshino2021] Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. (2021). https://pubmed.ncbi.nlm.nih.gov/33888596/ DOI: 10.1126/science.abe9985","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"a62b7b5b-786a-57e9-85e9-67c6912a5054","stable_key":"import-a9dd23c6-978a-5755-8bd8-f29bd1fe0cda","title":"Niacin: NAD metabolism, deficiency and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"a8cac59639322f74812ce12eef338c2f6c385c04cc4af6ab511fc7c972f0c2e6","revision_id":"bec8fc45-12e7-5f75-a814-5d72ed015d01","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}